P. Salvà, J. Costa: Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. In: Clin Pharmacokinet. 29. Jahrgang, Nr.3, September 1995, S.142–53, doi:10.2165/00003088-199529030-00002, PMID 8521677.
J. A. Sutton, R. P. Clauss: A review of the evidence of zolpidem efficacy in neurological disability after brain damage due to stroke, trauma and hypoxia: A justification of further clinical trials. In: Brain Inj. 31. Jahrgang, Nr.8, 2017, S.1019–1027, doi:10.1080/02699052.2017.1300836, PMID 28534652.
A. T. Che Has, N. Absalom, P. S. van Nieuwenhuijzen, A. N. Clarkson, P. K. Ahring, M. Chebib: Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface. In: Sci Rep. 6. Jahrgang, Juni 2016, S.28674, doi:10.1038/srep28674, PMID 27346730, PMC 4921915 (freier Volltext).
P. Salvà, J. Costa: Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. In: Clin Pharmacokinet. 29. Jahrgang, Nr.3, September 1995, S.142–53, doi:10.2165/00003088-199529030-00002, PMID 8521677.
J. A. Sutton, R. P. Clauss: A review of the evidence of zolpidem efficacy in neurological disability after brain damage due to stroke, trauma and hypoxia: A justification of further clinical trials. In: Brain Inj. 31. Jahrgang, Nr.8, 2017, S.1019–1027, doi:10.1080/02699052.2017.1300836, PMID 28534652.
A. T. Che Has, N. Absalom, P. S. van Nieuwenhuijzen, A. N. Clarkson, P. K. Ahring, M. Chebib: Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface. In: Sci Rep. 6. Jahrgang, Juni 2016, S.28674, doi:10.1038/srep28674, PMID 27346730, PMC 4921915 (freier Volltext).